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Its NS4A Cofactor Peptide for Optimal Binding
of a Boronic Acid Inhibitor as Shown by NMR
by residues His57, Asp81, and Ser139. In this complex,
the protease domain has the same conformation as in
a complex of full-length NS3 (protease and helicase
domains) with NS4A peptide [9]. The peptide interca-
lates into the N-terminal domain and forms one strand
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in a crystal structure of protease alone, the N-terminal
residues (1–30) are extended away from the protein [10].
Thus, the N-terminal domain must undergo substantialSummary
rearrangement, as well as additional changes at the ac-
tive site that optimize the location of residues His57NMR spectroscopy was used to characterize the hepati-
tis C virus (HCV) NS3 protease in a complex with the 24 and Asp81 relative to Ser139 [8]. In the NMR solution
structure of NS3 protease alone, the C-terminal domainresidue peptide cofactor from NS4A and a boronic acid
inhibitor, Ac-Asp-Glu-Val-Val-Pro-boroAlg-OH. Second- and hydrophobic core resemble the conformation in the
binary complex, while the N-terminal  strand A0 andary-structure information, NOE constraints between
protease and cofactor, and hydrogen-deuterium ex- helix 0, which fold along the peptide in the X-ray struc-
ture of the complex, are unstructured [11]. Likewise, anchange rates revealed that the cofactor was an inte-
gral strand in the N-terminal -sheet of the complex engineered single-chain NS4A-NS3 protein in which the
NS4A peptide was tethered to the N terminus of NS3as observed in X-ray crystal structures. Based upon
chemical-shift perturbations, inhibitor-protein NOEs, protease via a four-residue linker lacked well-defined
structure for the NS4A residues and the first 30 NS3and the protonation state of the catalytic histidine,
the boronic acid inhibitor was bound in the substrate residues [12]. In this single-chain protein, however, an
NOE was identified between NS4A and NS3 (HN-Gly27binding site as a transition state mimic. In the absence
of cofactor, the inhibitor had a lower affinity for the to HN-Ile135), suggesting that NS4A might adopt the
conformation seen in the crystal structure of NS3/NS4A.protease. Although the inhibitor binds in the same lo-
cation, differences were observed at the catalytic site Despite disorder in the N terminus, the presence of NS4A
induced proper alignment of the catalytic triad as evi-of the protease.
denced by key NOEs and the downfield chemical shift
of His57 backbone amide proton [12].Introduction
Structural information on the interaction of NS3 and
NS3/NS4A with active site inhibitors has provided con-Hepatitis C virus (HCV) currently infects approximately
3% of the world population and can lead to liver cirrhosis formational details of protein/inhibitor interactions.
X-ray crystal structures of NS3/NS4A complexed withand hepatocellular carcinoma. As with other members of
the Flaviviridae family, HCV is a single-stranded positive two -ketoacid inhibitors (Boc-Glu-Leu-NH-CH(CH2CHF2)
CO-COOH and Z-Ile-Leu-NH-CH(CH2CHF2)CO-COOH)RNA virus that encodes a large (approximately 3000
amino acid) polypeptide. Maturation of this HCV poly- [13] and an NMR solution structure of NS3 with an
-ketoacid inhibitor (Boc-Glu-Leu-NH-CH(CH2CHF2)peptide into functional proteins requires cleavage at
distinct sites. One of its own protein products, NS3 ser- CO-COOH) [14] have been reported. In this series of
inhibitors, -CHF2 acts as a surrogate for -SH of the P1ine protease (the first 180 residues of NS3), cleaves
the HCV polypeptide in the NonStructural region at four Cys of the substrate (per the nomenclature of Schecter
and Berger [15], substrate and inhibitor positions arejunction sites: NS3-NS4A, NS4A-NS4B, NS4B-NS5A,
and NS5A-NS5B [1–3]. The nonstructural protein NS4A designated as …P3-P2-P1—P1-P2-P3…, with the scis-
sile bond between P1 and P1). The inhibitors are in ex-is required for in vivo cleavage at the NS4B-NS5A site
tended conformations, with Leu and Glu or Ile occupyingand enhances the cleavage rate at the other sites [4].
the P2 and P3 binding sites, respectively. The inhibitorOnly a portion of NS4A (residues 22–33) is necessary
carbonyl bonds with the active site serine, Ser139, tofor its NS3 cofactor activity, and replacement of the
form a hemiketal (Figure 1A); the oxyanion is hydrogenfull-length protein by an NS4A peptide is sufficient for
bonded to the active site histidine, His57; and the car-enhanced cleavage at junction sites NS4A-NS4B, NS4B-
boxylate occupies the oxyanion hole. This type of inter-NS5A, and NS5A-NS5B in vitro [5]. Because of the im-
action has also been observed for ketoacid analogs inportance of NS3 in the lifecycle of HCV, there has been
complex with thrombin [16]. In contrast, ketoacid inhibi-keen interest in understanding its activation by NS4A.
tors in complexes with trypsin and thrombin have alsoX-ray crystal structures of NS3 protease in complex
been characterized as “reaction intermediate analogs”with NS4A peptide [6–8] show that the protein adopts
[17], where R in Figure 1B is a p-amidinophenyl groupa chymotrypsin-like fold with the catalytic triad formed
[18]. In these analogs, the carbonyl is likewise bonded
to the active site serine, Ser195 (Ser139 in NS3), but1 Correspondence: charles.kettner@bms.com
the carboxylate and oxyanion are reversed, the former2 Present address: Bristol-Myers Squibb Company, Experimental
Station, Wilmington, DE 19880. hydrogen bonded to the histidine and the latter in the
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Figure 1. Models of Active Site Inhibitors of
Serine Proteases
Schematic representations were based on (A)
ketoacid binding as a hemiketal as in the crys-
tal structure of NS3/NS4A/ketoacid inhibitor
[13] and the NMR structure of NS3/ketoacid
[14], (B) ketoacid binding as a reaction inter-
mediate analog [18], and (C) boronic acid
binding as a reaction intermediate analog
[19].
oxyanion hole. This configuration mimics the tetrahedral Results and Discussion
intermediate expected for substrate hydrolysis, in which
addition of the active site serine to the carbonyl of the Complex Formation
Because NS4A is critical for the activity of NS3 protease,scissile bond results in formation of an acyl enzyme.
Structures of -ketoacid inhibitors in complex with NS3 we searched for protein and cofactor constructs that
allowed NMR study of the high-affinity complex. 1 H-15N[14] and with NS3/NS4A [13] showed that this type of
transition state analog was not present for these inhibi- HSQC (heteronuclear single-quantum correlation) spec-
tra [29] were used to monitor changes in chemical shiftstors. The pKa of the His57 imidazole is less than 5.7
[14] and thus further distinguishes it from a reaction of NS3 that result from interactions with the cofactor
peptide. Based on a construct used in crystal complexesintermediate analog where the histidine would be pro-
tonated (Figures 1B and 1C). [7], spectra of proteases from the 1b genotype showed
no changes upon addition of peptide 1b-16mer or theAlthough the high-resolution structures of inhibited
protease provide key insights into the binding of keto- longer 1b-23mer (Table 1). Increasing the glycerol con-
centration (10% v/v) enhanced peptide affinity, in agree-acid inhibitors, a good transition state analog would
yield additional information relevant to substrate hydro- ment with previous reports [30, 31], but resulted in
poorer quality NMR spectra because of increased vis-lysis. In crystallographic and NMR studies of boronic
acid inhibitors complexed with other serine proteases, cosity.
For protease from the 2a genotype, the addition ofthe boronic acids can act as “reaction intermediate ana-
logs” [19–22]. The active site serine makes a near tetra- NS4A peptide (1b-16mer or the longer 1b-23mer [Table
1]) resulted in improvements in peak dispersion andhedral adduct with the boronic acid, one borate -OH
occupies the oxyanion hole, and the other hydrogen substantial chemical-shift changes, consistent with
complex formation (Figure 2). On the other hand, thebonds with the histidine (Figure 1C). The active site imid-
azole ring NH groups are involved in strong hydrogen addition of peptides based on the 2a genotype (2a-
18mer or 2a-23mer [Table 1]) caused no spectralbonds, and the imidazole has a pKa  9 [20, 23].
Herein we describe NMR studies of NS3/NS4A in com- changes, implying low affinity for the protease. The abil-
ity of the 2a protease to bind peptides from other geno-plex with the peptide boronic acid inhibitor, Ac-Asp-
Glu-Val-Val-Pro-boroAlg-OH (InhI; boronic acid analog types more tightly than its cognate cofactor is in agree-
ment with a report that NS3 2a protease activity wasof allylglycine). This inhibitor mimics the sequence of a
good substrate for NS3 protease [24] and is expected stimulated more effectively by NS4A from alternate ge-
notypes [32]. In all subsequent experiments, NS3 2a andto bind in the substrate P6-P1 binding sites. The allylic
side chain is predicted to bind in a manner similar to NS4A 1b-23mer (or 1b-24mer) were used, a combination
that provided well-dispersed HSQC spectra in 2%the -CH2SH of Cys and the -CH2CHF2 side chain of the
ketoacid inhibitors. The allylic proton is polarized and glycerol.
The 1 H-15N HSQC spectrum of the 15N-NS3/NS4A com-can potentially interact with the aromatic ring of Phe154
in the bottom of the P1 pocket [24]. plex showed uniform linewidth peaks and good chemi-
cal-shift dispersion indicative of a folded protein (FigureTo date, NMR studies of NS3 protease inhibitors have
examined peptidic inhibitors in solution [25] and when 2). However, at the concentrations required for spectral
bound to NS3 [26–28]. NMR studies have also elucidated
the full three-dimensional structure of NS3 protease
Table 1. NS4A Cofactor Peptide Sequencesalone [11] and in complex with ketoacid inhibitors [14]
but not with bound NS4A cofactor. We have found sam- Peptide Sequence
ple conditions that optimize the affinity of cofactor for
1b-16mera KGSVVIVGRIILSGRKprotease, enabling the inhibitor-protease interactions to
1b-23merb KKGSVVIVGRIVLSGKPAIIPKK
be studied in solution with bound cofactor. Both the 1b-24merc KKGSVVIVGRIVLSGKPAIIPKKhS
protease and cofactor were enriched with 15N and 13C 2a-18merd KKGSVSIIGRLHVNQRKK
2a-23merd KKGCVCIIGRLHVNQRAVVAPKKisotopes, and backbone resonances were assigned for
both NS3 and NS4A in the NS3/NS4A/inhibitor complex. a The peptide sequence from the 1b genotype which was used in
We determined the effect of cofactor on inhibitor binding the crystallographic studies described in reference [7].
by comparing spectra of the protease in various states: b The peptide sequence from the 1a/1b genotype that was used in
the crystallographic studies described in reference [6].NS3, NS3/NS4A, NS3/inhibitor, and NS3/NS4A/inhibitor.
c This peptide was prepared isotopically enriched.The interpretation of the NMR data is based on pub-
d These peptides correspond to the sequence of NS4A from the 2alished structures and an NS3/NS4A/inhibitor model pre-
genotype.
sented herein.
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Positive and negative peaks are depicted by eight and one contours, respectively. Samples for spectra (A), (C), and (D) were prepared
sequentially by starting with (A) 150 M 15N-NS3 2a (1–192) in 25 mM MES (pH 6.5), 100 mM NaCl, 5 mM DTT, 2% glycerol, 6% D2O, adding
(C) 250 M InhI, and subsequently adding (D) 160 M NS4A. Alternating the order of addition (first adding NS4A then InhI) resulted in a
spectrum identical to (D). The sample for (B) contained 110 M 15N-NS3 and 135 M NS4A in the above buffer. All spectra were acquired with
64 transients, 64 complex increments in t1 (15N), 256 complex points in t2 (1 H), and spectral widths of 1886.79 Hz in t1 and 9259.26 Hz in t2,
with the 1 H carrier set on the water resonance and the 15N carrier set at 116 ppm. Spectral regions surrounding labeled peaks are boxed to
aid visual comparison between spectra.
assignments, significant line broadening was observed, 800 M. The 15N spin-spin relaxation time (T2) decreased
from 52 to 44 ms, likely reflecting partial sample aggre-and autoproteolysis (detected via SDS-Page gels and
mass spectrometry) occurred at unacceptable rates. gation.
Protein constructs used in the NS3 solution structuresAddition of the peptidic boronic acid inhibitor, Ac-
Asp-Glu-Val-Val-Pro-boroAlg-OH, stabilized the com- [11, 14] have a C-terminal poly-lysine tag, whereas the
single-chain NS4A-NS3 construct does not [12]. Weplex against autoproteolysis so that the protein concen-
tration could be increased to 1 mM, suitable for NMR have used an NS3 2a (1-181)Lys6 construct to acquire
a duplicate set of spectra in addition to those describedresonance assignments. The quality of the 1 H-15N HSQC
spectrum reflects a well-folded protein complex (Figure above. Similar spectral changes were observed, sug-
gesting that the C-terminal tag does not affect cofactor2). At less than one equivalent inhibitor, separate peaks
were seen for bound and free protein, indicating that or inhibitor binding.
The NS4A cofactor peptide was examined with andthe inhibitor did not dissociate from the complex on the
NMR time scale. At approximately one equivalent of without protease to detect conformational changes in
the peptide upon binding. The 1 H-15N HSQC spectrum ofinhibitor, the number and linewidth of the peaks imply a
firm inhibitor bound complex. Even under the optimized 15N-enriched NS4A in solution displayed little chemical-
shift dispersion, characteristic of an unstructured pep-sample conditions, there was some degradation in spec-
tral quality upon concentration of the sample from 180 to tide (Figure 3A), whereas binding to NS3 and inhibitor
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Kd  [NS4A], fit the data with a maximum velocity, Vmax,
of 0.075 0.007mol/l/min and a dissociation constant,
Kd, of 2.4  0.8 M. Finally, the affinity of NS3/NS4A for
InhI was determined (Figure 4D). The equation vi/vo 
1/(1  [Inh]/Kiapp), where vi and vo are the velocities in
the presence and absence of inhibitor and Kiapp (Ki
apparent) is Ki(1  [S]/Km), gave a good fit to the data.
Since the concentration of substrate, S, is 5.0 M and
Km is greater than 50 M (Figure 4A), Kiapp is equivalent
to Ki(13  2 nM) for competitive inhibition.
The binding of InhI to NS3 in the absence of NS4A
was also studied. Under conditions similar to those de-
scribed in Figure 4D, we determined the inhibition of
NS3 (100 nM) by using 500–1000 nM InhI levels. Between
6% and 26% inhibition was observed. This range of
inhibition was limited in order to maintain pseudo-first-
order reaction conditions. Handling the data in the same
manner as described in Figure 4D gave a Kiapp 160
35 nM (n  5).
Resonance Assignments and Secondary
Structure
NMR resonance assignments of the protease and pep-
tide are necessary in order to map observed NMR spec-
tral changes to specific residues in the protein. Because
the NS3/NS4A binary complex was susceptible to auto-
proteolysis, the resonance assignments were deter-
mined with the inhibitor bound. Backbone resonance
assignments were determined for 15N,13C-NS3 and for
15N,13C-NS4A in an NS3/NS4A/InhI complex with CBCA-
CONH, HNCACB, and HNCA triple resonance experi-
ments (Table 2) following well-established strategiesFigure 3. NMR Spectra of NS4A Cofactor Peptide
[34, 35]. Resonances were assigned for 95% of the back-1 H-15N HSQC spectra of (A) 900 M 15N-NS4A and (B) 115 M 15N-
bone HN, N, C, and C atoms for residues Thr4 toNS4A/NS3/InhI acquired with the parameters listed in Figure 2. Am-
Ser181 of NS3 and for all residues of NS4A, with theide assignments are shown for NS4A in the NS3/NS4A/InhI complex.
Note that amide peaks for C-terminal residues I237–hS242 overlap exception of the N-terminal Lys19 and the amides of
with peaks from unbound NS4A. Lys20 and Val30.
Secondary-structural elements were identified with
the chemical shift index (CSI) [36], where contiguous
resulted in increased chemical-shift dispersion (Figure stretches of large positive deviations 	
(C) are indica-
3B). This is consistent with the peptide adopting a well- tive of  helices and large negative 	
(C) and positive
defined conformation within the complex. 	
(C) are representative of  strands (Figures 5A and
5C). Of particular note were the CSIs that clearly delin-
eate the N-terminal  strand A0 and helix 0 (FigureEnzymatic Characterization of NS3/NS4A
Complex 5A). This strand and helix are present in X-ray crystal
structures of NS3/NS4A binary complexes [6–8], but inThe protease complex was characterized by measuring
the cleavage of a peptide substrate, Ac-Asp-Glu- NMR studies of the single-chain complex in solution,
there is no evidence of helix 0 [12]. Neither A0 norAsp(Edans)-Glu-Glu-Abu[COO]Ala-Ser-Lys(Dabcy)-
NH2 [33]. Figure 4A shows the catalytic activity of the 0 is observed in NMR [11] and crystallographic [10]
structures of NS3 alone. In our complex, strong sequen-NS3/NS4A complex as a function of substrate concen-
tration (2.5–200 M). A linear dependence of velocity tial amide-amide NOEs for residues Leu14–Arg24 pro-
vide additional evidence for the existence of a helicalversus substrate concentration was obtained and indi-
cated that the Km was greater than 50 M. From the structure, 0 (data not shown).
Most  strands were identified by both 	
(C) andslope of this plot, kcat/Km was found to be 5.4  105 
1.3  104 M1s1. 	
(C) (Figure 5A). The CSI analysis also suggested the
existence of an additional strand for residues 91–95;Catalytic activity was highly dependent on the pres-
ence of the NS4A cofactor. As shown in Figure 4B, NS3 although this region is not a  strand in the crystal struc-
ture, it is relatively extended. The only NS3 secondary-was approximately 50-fold less active in the absence of
NS4A. We determined the dissociation constant for the structural element observed in the crystal structures
that was not identified by the CSI methodology was theNS3/NS4A complex by measuring enzymatic activity as
a function of NS4A concentration (Figure 4C). The equa- 1 helical turn. However, Tyr56, His57, and Ala59 had
C shifts consistent with a helix (although Gly58 didtion describing the reaction velocity, v  Vmax[NS4A]/
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not), and residues His57–Ala59 had amide-amide NOEs
consistent with the helical turn.
For NS4A, the	
(C) and	
(C) values were predom-
inantly negative and positive, respectively, indicating that
the peptide adopts a  strand conformation when it is
bound to protease (Figure 5C). Strict adherence to the
CSI approach for both C and C shifts delineates a
 strand only from residue Arg28–Ser32, although sev-
eral other residues had shifts that were strongly sugges-
tive of a longer  strand. Overall, the secondary-struc-
tural elements identified in this study are in agreement
with those reported in the NS3/NS4A crystal structure,
and the minor discrepancies reflect a limitation of this
statistical method rather than significant conformational
differences [36].
HN-HN crosspeaks between the peptide and protease
were measured in a 13C-filtered, 15N-selected NOE spec-
troscopy (NOESY) experiment on 15N,13C-NS3/15N,13C-
NS4A/InhI. NOE crosspeaks were observed between
NS3 and NS4A amide protons for Gln8–Arg28, Gln32–
Ile29, Val33–Ile29, Val35–Gly27, Ser37–Val24, and
Ala65–Val23. These six intermolecular NOEs were con-
sistent with short ( 4 A˚) interproton distances predicted
by the crystal structure (PDB code 1jxp) [7] (modeled
with hydrogens added) and are sufficient to orient NS4A
relative to NS3. In addition, a strong intramolecular NOE
between the amides of Val26 and Gly27 in NS4A sug-
gests a short interproton distance; in the crystal struc-
ture, a small kink in the middle of the strand brings the
amide protons of Val26 and Gly27 into close proximity.
From the crystal structure, NOEs would also be ex-
pected between Tyr6 and Val30 and between Thr4 and
Ser32; these could not be identified because the amide
of Val30 is unassigned and the amide protons of Thr4
and Ser32 are degenerate. The good correlation be-
tween NOEs from NMR data and short distances in the
crystal structure implies that the bound peptide adopts
a similar conformation in solution as in the X-ray crystal
structures of NS3/NS4A [6–8].
Our complex appears to maintain more structure in the
N terminus than the single-chain NS4A-NS3 1a. Virtually
complete resonance assignments were determined for
the protease and the peptide, whereas assignments
were missing for almost all residues between Ile3 and
Val33 of the single-chain construct and only 3 of the 12
residues in the NS4A segment could be assigned [12].
(B) Comparison of catalytic activities of NS3 in the presence and
absence of NS4A. NS3 (0.38 nM) was incubated for 10 min in the
presence (squares) and absence (circles) of 10 M NS4A at pH 7.0
and 25C. Substrate was added to give a final concentration of
5.0 M, and enzymatic activity was monitored by measuring the
increase in fluorescence with time.
(C) Hydrolysis rates as a function of NS4A concentration. The activity
of NS3 (1.0 nM) was measured in the presence of varying amounts
of NS4A as described in (B). The equation, velocity  Vmax[NS4A]/
Figure 4. Enzymatic Characterization of the Protease Kd  [NS4A], where Vmax is the maximum velocity and Kd is the
(A) Substrate hydrolysis rates as a function of substrate concentra- dissociation constant, was fit to the data. The following values were
tion. NS3 (0.38 nM) was incubated with 10 M NS4A for 5 min obtained: Kd  2.4  0.8 M and Vmax  0.075  0.007 mol/l/min.
at pH 7.0 and 25C. Substrate, Ac-Asp-Glu-Asp(Edans)-Glu-Glu- (D) Effect of InhI on NS3 activity. The activity of NS3 (NS4A) at
Abu[COO]Ala-Ser-Lys(Dabcy)-NH2, was added to the final concen- varying concentrations of InhI (Ac-Asp-Glu-Val-Val-Pro-boroAlg-
tration indicated on the x axis. Hydrolysis rates were determined OH) was determined as described in (B) except that a NS3 concen-
via HPLC (see Experimental Procedures). tration of 5.0 nM was used.
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Table 2. NMR Data Acquisition Parameters for All Experiments
Spectral Width Carrier Acq. Time Complex
Experiment Dimensions (Hz) (ppm) (ms) Points Transients Reference
2D 1H-15N HSQC 15N-f1 1,886.79 116.0 33.9 64 64 [29, 61]
1H-f2 9,259.26 4.773 27.6 256
2D 1H-15N HSQC 15N-f1 5,000.00 180.0 6.4 32 128 [29, 61]
1H-f2 19,230.77 4.773 26.6 512
2D 1H-15N LR-HSQCa 15N-f1 1,886.79 180.0 28.2 256 256 [43]
1H-f2 9,259.26 4.773 27.6 256
3D CBCA(CO)NHb,c 13C-f1 9,615.39 46.0 5.8 56 32 [62, 63]
15N-f2 1,886.79 116.0 24.4 46
1H-f3 9,259.26 4.773 27.6 256
3D HNCACBb,c 13C-f1 9,615.39 46.0 5.0 48 32 [64–66]
15N-f2 1,886.79 116.0 24.4 46
1H-f3 9,259.26 4.773 27.6 256
3D HNCAb 13C-f1 4,000.00 56.0 12.0 48 32 [69, 68]
15N-f2 1,886.79 116.0 24.4 46
1H-f3 9,259.26 4.773 27.6 256
3D HNCOb,d 13C-f1 2,500.00 176.0 16.8 42 32 [67]
15N-f2 1,886.79 116.0 22.3 42
1H-f3 9,259.26 4.773 27.6 256
3D 13C-filtered,
15N-selected NOESYc,e 1H-f1 8,196.72 4.773 15.6 128 16 [69]
15N-f2 1,886.79 116.0 26.9 32
1H-f3 9,259.26 4.773 27.6 256
a Long-range HSQC with 22 ms delay for evolution of 1HC15N couplings.
b Acquired on 15N,13C-NS3 2a(1–181)Lys6/NS4A/InhI.
c Acquired on 15N,13C-NS3 2a(1–181)Lys6/15N,13C-NS4A/InhI.
d Acquired in the presence and absence of inhibitor.
e Acquired with a 100 ms mixing time.
The higher degree of structure in our NS3 2a complex necessary for a structured N-terminal domain because
a protease/peptide complex was achieved without in-relative to the single-chain 1a protein may be due to
amino acid differences between constructs or due to hibitor (Figure 2B). The amide chemical shifts for resi-
dues in  strand A0 and helix 0 were insensitive tothe linkage of NS4A to the N terminus of NS3 in the
single-chain construct. The latter explanation seems inhibitor binding (Figure 5B), demonstrating that the
backbone conformations of these N-terminal residuesless plausible since single-chain NS4A-NS3 is consider-
ably more active than its binary complex, implying that were not perturbed by the inhibitor.
the linkage is advantageous [37]. Thus, we attribute our
more regular secondary structure in the N terminus to Solvent Accessibility of NS4A Bound to NS3
Hydrogen-deuterium exchange experiments were useddifferences in primary sequence. This conclusion is sup-
ported by our observation that NS3 2a has a higher to identify protons that were well protected from ex-
change with water in the NS3/NS4A/InhI complex. Incofactor affinity than NS3 1b, whose sequence is more
similar to that of NS3 1a (see the section titled, “Complex these experiments, a protein sample in H2O buffer is
exchanged into D2O buffer before acquisition of a 1 H-15NFormation”). This is also consistent with reports on NS3
1b constructs in which the dissociation constants for HSQC; amide protons protected from solvent are then
observable, whereas exchangeable protons are not. Athe protease-peptide complexes are dependent on NS3
sequence [31]. In this same study, the first 21 residues third of the NS3 amide protons were observable after
30 min at 25C in D2O, and two-thirds of these were stillof NS3 1b exhibited high proteolytic susceptibility in
the N terminus with and without cofactor, suggesting detectable after an additional 16 hr. This persistence
reflects a globular, well-folded protein.flexibility in this region even in the presence of cofactor
[31]. It has been postulated that the structured N termi- In the N-terminal domain, the amide protons of resi-
dues 33–37 ( strand A1) and residues 23–27 and 29nus previously observed only in crystal structures may
require crystal contacts [31, 12]; our data are consistent ( strand D1 of NS4A) were in slow exchange. Based
on the published crystal structure (PDB code 1jxp) [7],with a well-structured NS3 2a N terminus without these
stabilizing interactions. hydrogen bonds would be expected between the am-
ides of NS3 residues Val33, Val35, and Ser37 and theThe chemical-shift and NOE data reported here were
obtained with bound inhibitor that may contribute to carbonyls of NS4A, whereas amides of Val24, Val26,
Gly27, and Ile29 would be hydrogen bonded to theordering the N terminus of the protein. In the literature,
limited proteolysis studies on NS3 1b have shown that carbonyls of  strand A1. The slow exchange rates of
the Val23 and Ile25 amides are in accord with theirthe addition of inhibitor increased stability in both the
N-terminal and C-terminal domains of the protein [38]. buried state predicted by the crystal structure [7]. The
amide of Arg28 in NS4A, hydrogen bonded to the car-In our studies of NS3 2a, inhibitor was apparently not
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Figure 5. Summary of Secondary Structure and Chemical-Shift Perturbations for NS3/NS4A/InhI
(A) 	
 13C and 	
 13C were calculated by subtracting the random coil values from the measured 13C and 13C chemical shifts for 15N,13C-
NS3/NS4A/InhI. Secondary-structure elements as determined from chemical-shift indices according to the method of Wishart and Sykes [36]
are depicted as gray arrows for  strands and open rectangles for helices. Secondary-structure features from the NS3/NS4A crystal structure
[7] are depicted as black arrows for  strands and solid rectangles for helices.
(B) The weighted chemical-shift perturbations 	
Inh  |	
1 H|  0.5*|	
15N| are calculated for amides of 15N-NS3/NS4A relative to 15N-NS3/
NS4A/InhI. Broken bars indicate 	
C  5 or 	
C  5 in (A) and 	
Inh  4 in (B).
(C) 	
 13C and 	
 13C as described in (A) but for the NS4A peptide in NS3/15N,13C-NS4A/InhI .
bonyl of Gln9 of NS3 in the crystal structure, has a Inhibitor Binding Model
We used high-resolution structures of NS3 in solutionmoderate exchange rate and is the only amide facing
 strand A0 that is not in rapid exchange. The slow [11] and NS3/NS4A in crystals [6–8] to interpret our NMR
chemical-shift and limited NOE data and to then con-hydrogen-deuterium exchange rates for many amide
protons of peptide  strand D1 and protease  strand struct a model of inhibitor binding. The locations of sec-
ondary-structural elements and NS4A binding in the ter-A1, along with NOE and chemical-shift data, indicate a
strong association between NS4A and NS3. nary complex were in agreement with the published
crystal structures, thus justifying the use of these struc-Although the amide protons in NS4A were in slow
exchange,  strand A0 and helix 0 protons that lie tures in interpreting our NMR data.
Amide chemical-shift perturbations were used toalongside the cofactor in the crystal structure were in
rapid exchange. These regions adopted regular second- identify the inhibitor binding site. Sample degradation
prevented making full assignments on uninhibited pro-ary structure on the NOE time scale (100 ms), whereas
on the longer time scale of the hydrogen-deuterium ex- tein. As an alternative, the amide assignments for NS3/
NS4A utilized 3D HNCO data that were acquired on 0.3change experiment (1000 s), protons in this region were
labile. Thus, the N terminus of NS3 2a may not be com- mM protein samples in less than two days. 3D HNCO
experiments provide three chemical shifts (HN, N, andpletely rigid in the presence of cofactor.
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NS3 1a construct [12] with chemical shifts similar to
those of Tyr56 and His57 in our ternary complex. Adja-
cent residues (for example Gly58 and Ala59, see Figures
2B and 2D) exhibited only moderate chemical-shift
changes and were weaker in intensity in the absence
of inhibitor. The perturbations were localized near the
substrate binding site; the fact that the largest chemical-
shift perturbations were on the unprimed side points to
that as the location of InhI binding (Figures 5B and 6).
This binding site is consistent with published structures
of an NS3/ketoacid inhibitor complex in solution [14] and
NS3/NS4A/ketoacid inhibitor complexes in crystals [13].
A 3D 13C-filtered, 15N-selected NOE experiment was
used to identify NOEs between the inhibitor and the
protein backbone. NOE crosspeaks were observed be-
tween the inhibitor P3Val and P4Val sidechain protons
and the amide protons of Ala157 and Cys159, between
the inhibitor P1allyl H and Ala157 amide proton, be-
tween the inhibitor P3Val amide and Ala157 amide pro-
tons, and between the P1allyl H and H protons and
Gly137 amide proton. These NOEs reflect short dis-
tances between the inhibitor and the protein and there-
fore define the orientation of the bound inhibitor.
To visualize these NOEs, we built a computer model
of the inhibitor docked in the unprimed portion of the
NS3/NS4A binding site. Coordinates of the protein andFigure 6. Chemical-Shift Perturbations Mapped onto a Model
Structure of NS3/NS4A/InhI its cofactor were based on an energy minimized crystal
The model was calculated from the crystal structure of NS3/NS4A structure of the 1b construct, PDB code 1jxp [7]. Where
[7] as described in the text. The inhibitor is depicted in stick repre- necessary, side chains were mutated in accord with the
sentation (white C, blue N, red O, and green B), NS4A (violet) and 2a sequence. There are no differences between 1b and
NS3 are shown as ribbons. The catalytic triad (His57, Asp81, and 2a protein sequences in the region close to the active
Ser139) are in stick representation (magenta C, blue N, and red O).
site.Residues whose backbone amide resonances shift more than 0.2
The peptide inhibitor used in the model was Ac-Val-ppm and 0.1–0.2 ppm (	
Inh in Figure 3B) upon binding InhI are
Val-Pro-NHCH(CH2SH)C(OH)-(OCH3)(O of Ser139). Thecolored red and orange, respectively. Residues Tyr56, His57,
Gly137, Ser138, and Ser139, which could not be identified in the two N-terminal acidic residues were not modeled be-
absence of InhI, are colored yellow. This figure was generated with cause earlier docking experiments (Z.R.W., unpublished
Molscript [58] and Raster3D [59]. data) indicated that due to numerous positively charged
residues abutting the binding site (Arg109, Arg118,
Lys119, Arg122, Arg123, Arg130, Lys136, Arg155,
C) and allow the correlation of assignments for NS3/ Arg161, and Lys165) there were many possible orienta-
NS4A and NS3/NS4A/InhI. Many of the amide assign- tions of the N-terminal Asp-Glu, and it was not possible
ments could be transferred to the binary complex, en- to determine which might be preferred. Previous studies
abling measurement of chemical-shift perturbations for employed cysteine as P1, and we thought it a suitable
a majority of the protease residues (Figure 5B). substitute for the allyl side chain. In place of boron, we
Most of the chemical-shift changes occurred in the used carbon in a tetrahedral conformation bonded to
C-terminal domain, whereas signals from residues of the O of Ser139. This necessitated that His57 acquire
the N-terminal domain that were not directly adjacent a proton and be positively charged.
to the active site showed little or no perturbation upon The inhibitor was manually oriented in a position pre-
inhibitor binding. All of the residues exhibiting large per- viously determined from computer simulations of related
turbations were located near the loop containing Ser139 tetrapeptides and peptide mimetics (Z.R.W., unpub-
and residues 156–159 of  strand E2 (Figure 6), a region lished data). The system was then minimized with the
that defines the substrate binding site of NS3 protease. program AMBER [40, 41] and further relaxed by 20 ps
The largest changes occurred for residues in the regions of molecular dynamics. The simulation made use of
123–125, 136–141, and 154–170 (Figure 5B). The amide AMBER’s “belly” option, allowing the inhibitor and most
resonances for residues of the oxyanion hole (Gly137, residues within 12 A˚ of its initial position to move freely
Ser138, and Ser139) could not be identified in the ab- except for the protein’s main chain atoms, which were
sence of inhibitor. This is also the case for -lytic prote- constrained with a weak force constant of 1.0 kcal/
ase, another serine protease [39], and may be the result mol·A˚2 . Because of the preponderance and ambiguity
of spectral overlap or intermediate chemical exchange of NOE constraints involving the two valine residues
in the uninhibited protein. Likewise, the amide peaks for of the inhibitor, all three rotamers of each valine were
Tyr56 and His57, which are well isolated in the HSQC considered as starting conformations, necessitating a
spectrum of NS3/NS4A/InhI, could not be assigned in total of nine computer runs. The conformations used for
the absence of inhibitor (Figure 2). These amide reso- analysis were the averages over the last 3 ps of each
simulation.nances have been assigned for the single-chain NS4A-
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15N2 chemical shifts with aliphatic 1H1 and 1H
2 pro-
tons [43, 44]. This spectrum of 15N NS3/NS4A/InhI in D2O
exhibited sets of peaks for His57 and His149 (Figure
7B). His149 showed nitrogen chemical shifts character-
istic of neutral histidine, with a proton residing on the
N2 nitrogen, leaving N
1 to complex with the structural
zinc [44, 45]. This tautomeric state agrees with previous
NMR characterization of His149 in NS3 alone and in NS3
complexed with ketoacid inhibitors [14, 46]. Nitrogen
resonances at 181.5 ppm and 181.9 ppm correlated with
His57 amine peaks at 16.2/182.6 ppm and 15.7/182.9
ppm in the side chain HSQC (accounting for the deute-
rium isotope effect). We do not know why there are two
sets of peaks for His57, although one explanation is that
there are two slightly different conformations at the site
of the boronic acid. The backbone amides of residues
137–140, which span the oxyanion hole, also had two
sets of peaks with similar chemical shifts. The doubling
of peaks is restricted to these immediate neighbors,
suggesting that residues with more than one conforma-
tion are localized within the region surrounding the oxya-
nion hole. The 15N
1 and 15N2 chemical shifts for bothFigure 7. Side Chain HSQC and Long-Range HSQC Spectra of Histi-
peaks are characteristic of protonated histidine [20, 45].dine Imidazole
Detailed NMR studies on other serine proteases in com-(A) Imidazole region from 1H-15N HSQC spectrum of 650 M 15N-
plex with boronic acid inhibitors have shown that theNS3/NS4A/InhI in H2O buffer. The spectrum was acquired with 512
imidazole chemical shifts clearly distinguish whether thetransients, 32 increments in t1 (15N), 512 complex points in t2 (1H),
and spectral widths of 5000 Hz in t1 and 19,230.77 Hz in t2, with the boronic acid forms a histidine or serine adduct, the latter
1H carrier set on the water resonance and the 15N carrier set at 180 a model of transition state binding [23]. For boronic acid
ppm. inhibitors in complex with -lytic protease, the frequency
(B) 1H-15N long-range HSQC spectrum of 15N-NS3/NS4A/InhI in D2O difference between the nitrogens is approximately 30
buffer acquired with the parameters used in (A) except with the 15N
ppm for histidine adducts and approximately 3 ppm forcarrier centered at 210 ppm, 1024 transients, and a 22 ms delay to
serine adducts. The 7 ppm frequency difference that isallow long-range 1HC-15N couplings to evolve. Coupling patterns are
observed for InhI complexed to NS3 is more like a serinedepicted for histidine imidazoles.
adduct.
The pKa of His57 in the NS3/NS4A/InhI complex was
determined by acquiring 1H-15N long-range HSQC spec-For comparison with NMR measurements, interactive
tra over a range of pH values (6.5, 7.0, 7.5, 8.1, 9.1, 10.4).graphics were used to add hydrogen atoms, and the P1
At pH  8, the sample showed significant degradationcysteine side chain was changed to allyl. In only one of
and peaks were lost in the noise. Throughout the observ-the nine computer models were the inter-atom distances
able pH range, the His57 imidazole chemical shifts werein agreement with the NOE data; that conformation is
consistent with a protonated histidine, indicating thatshown in Figure 6. This model of NS3/NS4A/InhI in con-
the pKa of His57 imidazole was greater than 8. In thejunction with NMR resonance assignments allows us
sidechain HSQC, one amine peak is observed (for eachto interpret our data in the absence of full structure
conformation) suggesting that, although the imidazole isdetermination.
protonated, only one amine is in slow enough exchange
with water to be observed in the HSQC.
His57 Imidazole The pKa  8 for His57 in the NS3/NS4A/InhI complex
Chemical shifts of the active site imidazole were used is consistent with the boronic acid complex acting as a
to further characterize the bound state of InhI. In a 1H- transition-state mimic and with NMR studies of other
15N HSQC spectrum of 15N NS3/NS4A/InhI with the 15N serine proteases [20]. The pKa of His57 in NS3 alone is
carrier centered at the frequency of the imidazole nitro- close to pH 6.6 [46]. Our results with the boronic acid
gens (180 ppm), there were two amine peaks that had are in contrast to those reported for ketoacid in complex
proton chemical shifts located considerably downfield with NS3 1b where His57 is neutral at physiological pH
in the proton specrum (16.2 ppm and 15.7 ppm; Figure (pKa  5.7) [14]. These differences are not surprising
7A). Downfield shifts for imidazole protons at the cata- since the mechanism of binding of the ketoacid (Figure
lytic site in serine proteases have been attributed to the 1) is considerably different from that expected for the
hydrogen bond network of the catalytic triad (Asp81, boronic acid inhibitor. Furthermore, the binding of the
His57, and Ser139 according to the NS3 protease num- boronic acid inhibitor is highly dependent on the pres-
bering) [20, 23]. In the presence of boronic acid inhibi- ence of the NS4A cofactor, as discussed in the following
tors, these protons are shifted even farther downfield, section.
indicating additional stabilization of the Asp-His hydro-
gen bond [42]. Effect of NS4A on Inhibitor Binding
The imidazole resonances were assigned in a 1H-15N The relative inhibition constants for InhI in the presence




35 nM) indicate that the binding of InhI is approximately
10-fold weaker in the absence of cofactor. To identify
how the cofactor might influence binding, the 1 H-15N
HSQC spectrum of NS3/InhI was compared with spectra
of NS3 alone and in complex with cofactor, with and
without inhibitor (Figure 2). The NS3/InhI spectrum was
considerably lower in quality than the other three. Amide
peaks for the first 50 residues were substantially shifted,
and few could be identified. In contrast, it was possible
to assign three-fourths of the backbone amides of the
C-terminal domain because in most cases the chemical
shifts were similar or identical to those in the ternary
complex.
Comparison of the spectra of NS3 and NS3/InhI with
and without NS4A gave distinctive insights into the role
of this cofactor. First, chemical shifts of many C-terminal
domain residues that were sensitive to inhibitor binding
(see Figure 5B) showed little or no change in the absence
of NS4A. These inhibitor-sensitive, cofactor-insensitive
peaks included residues 157–160 in  strand E2, 165–
170 in the adjacent strand F2, and residues 132–135 in
Figure 8. Regions Extracted from 1 H-15N HSQC Spectra in Figure 2helix 2. Particularly relevant are the amide peaks for
Depict How the NS4A Cofactor Influences Inhibitor Binding
A157 and C159, which in the ternary complex exhibited
(A and B) Spectra of 15N-NS3/NS4A (black) and 15N-NS3 (red) show
NOEs to the side chain protons of P4Val, P3Val and P1allyl the effect of cofactor in the absence of inhibitor. (C and D) Spectra
of the peptide boronic acid inhibitor and showed little of 15N-NS3/NS4A/InhI (black) and 15N-NS3/InhI (red) demonstrate the
change in the absence of cofactor. This suggests that effect of cofactor with inhibitor bound. (A) Without inhibitor, the
amide peaks of Leu44 and Thr46 are largely unaffected by cofactor,this portion of the inhibitor adopts the same bound con-
(C) whereas with inhibitor bound, they are broadened beyond detec-formation as in the ternary complex.
tion in the absence of cofactor. The amide peak of G162 is unaf-In contrast to the binding of the side chains of the
fected by cofactor and shifts substantially upon inhibitor binding (B
peptide inhibitor, the residues involved in catalysis were and D).
very dependent on NS4A binding. A number of peaks
at the catalytic site were absent (or extremely weak) in
the spectrum of NS3/InhI, including those of residues hibitor [13] [ketoacid inhibitor is Boc-Glu-Leu-NH-
56–59 (Figures 2A and 2D) and residues Gly137, Ser138, CH(CH2CHF2)C(O)-COOH]. On the other hand, sensitivity
and Ser139 of the oxyanion hole. Adjacent to this site, to cofactor at the catalytic site differs from that of the
resonances of L44, G45, and T46 were not detected in ketoacid binary complex, for which a downfield-shifted
the NS3/InhI complex, even though well-defined peaks His57 N
 proton indicative of a His57-Asp81 hydrogen
were observed in spectra of NS3, NS3/NS4A, and NS3/ bond was observed [14]. It has been pointed out that
NS4A/InhI (Figure 8). These resonances, as well as the the cofactor peptide might not have an essential role in
larger number of other missing peaks in the N-terminal the alignment of catalytic residues in the presence of
domain, are presumed to be broadened beyond detec- an inhibitor or substrate with a hydrophobic P2 residue
tion. This broadening does not reflect the chemical ex- [14]. For the boronic acid inhibitor examined here, with
change of inhibitor molecules on and off the protein P2 proline, the NS3 2a catalytic site is indeed sensitive
since the peak intensities and shifts of other inhibitor- to cofactor. The influence of cofactor on the affinity of
sensitive peaks were indicative of complete binding (see protease for inhibitor is consistent with observations
G162 in Figure 8). More likely, the loss of peaks adjacent made for the NS3 1a single-chain protein, in which the
to the catalytic site is indicative of conformational heter- cofactor induced changes at the catalytic site [12]. The
ogeneity at this site. cofactor dependence of the boronic acid inhibitor bind-
In the side chain HSQC of 15N NS3/InhI, the intensity ing parallels changes seen for enzymatic activity, for
of the catalytic imidazole peaks relative to the backbone which the presence of cofactor increases hydrolysis
amide signals was only one tenth that for the ternary rates ([5, 30, 47, 48] and Figure 4B). Overall, the NMR
complex. This suggests that although the catalytic site and enzymatic data are consistent with the boronic acid
may lack well-defined structure in the absence of cofac- inhibitor acting as a good mimic for cofactor-dependent
tor, a fraction of the population may still adopt a transi- substrate hydrolysis.
tion state binding mode.
The 10-fold loss in binding affinity described above
Significancecorrelates with environmental changes at the catalytic
site, whereas the peptide portion of the inhibitor, partic-
Careful choice of NS3 and NS4A constructs was criti-ularly P1, P3, and P4 sites, is associated with little or no
cal for obtaining a binary complex in solution underchange. Insensitivity to cofactor for the peptide portion
suitable concentrations for NMR and other biophysicalof the inhibitor is in agreement with similarities between
studies. NS3 protease from the HCV 2a genotype cou-the solution structure of NS3 1b/ketoacid inhibitor [14]
and the crystal structure of NS3 1b/NS4A/ketoacid in- pled with a peptide based on NS4A from the HCV 1b
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glycerol, 10 mM DTT (dithiothreitol) plus DNase, and 10 mM MgCl2genotype formed stable NS3/NS4A and NS3/NS4A/in-
and were lysed. The supernatant was loaded onto an S-Sepharosehibitor complexes at low glycerol concentrations. NOE
FF column (Pharmacia), washed, and eluted at 200 mM NaCl. Frac-and hydrogen exchange data show the essential inte-
tions containing NS3 were combined, concentrated, and purified by
gration of the cofactor into the N-terminal  sheet of size exclusion chromatography. Pure fractions were combined and
the protease, as has been observed in crystal struc- dialyzed against NMR buffer and concentrated. The yield of purified
protein was 5 mg/l growth.tures. This solution complex mimics the most active
Isotopically enriched NS4A 1b peptide was expressed in the Nova-state of the protease and paves the way for high-
gen’s peptide expression system with ketosteroid isomerase (KSI)resolution structure determination of NS3/NS4A com-
as a fusion protein tag [50]. Two complementary oligos (with over-plexes in solution.
hangs) were used: AAGAAAGGTTCTGTTGTTATTGTTGGTAGAATT
We examined the binding of a boronic acid inhibitor, GTTTTATCTGGTAAACCGGCTATCATCCCGAAAAAGATG and CTT
Ac-Asp-Glu-Val-Val-Pro-boroAlg-OH (Ki  13 nM), to TTTCGGGATGATAGCCGGTTTACCAGATAAAACAATTCTACCAAC
AATAACAACAGAACCTTTCTTCAT. After phosphorylation with T4NS3 protease with and without bound cofactor. The
polynucleotide kinase, the two oligos were mixed at a 1:1 ratio andinhibitor binds in an antiparallel manner to  strand E2
were heated at 99C for 10 min, 55C for 3 min, and 30C for 10 minand interacts with the unprimed sites of the substrate
for complete annealing. The “glassmilk” (Bio101 Mermaid System,binding pocket. Chemical shifts of His57 imidazole ni-
Vista, CA) was used for purification of this synthetic mini-gene,
trogens and pH titration studies demonstrated that, in which was then ligated into the expression vector pET31b.
the NS3/NS4A/inhibitor complex, the inhibitor be- KSI-NS4A-His6 vector was transformed into E. coli BL21 (DE3)
cells grown at 37C in MOPS minimal media with (15NH4)2SO4 or bothhaved like a reaction intermediate analog. In the ab-
(15NH4)2SO4 and [13C6]glucose. The peptide was isolated accordingsence of cofactor, inhibitor binding was an order of
to published procedures [50]. In brief, the insoluble pellet containingmagnitude weaker. NS3 residues interacting with the
KSI-NS4A-His6 was suspended in 8M GnHCl, sonicated, and purifiedpeptide portion of the inhibitor showed little change
on a Ni-NTA column (Qiagen). Fractions containing KSI-NS4A-His6upon binding cofactor, whereas residues adjacent to were combined and dialyzed against water to precipitate the fusion
the catalytic site were highly sensitive to cofactor, peptide. The fusion peptide was dissolved in 88% formic acid and
cleaved with the addition of cyanogen bromide. The NS4A peptidesuggesting that the lower affinity was due to changes
(KKGSVVIVGRIVLSGKPAIIPKKhS, where “hS” is homoserine) wasat the catalytic site. The importance of cofactor for
purified by HPLC.transition state-like binding highlights the critical role
Mass spectroscopy and N-terminal sequencing were used to con-of cofactor for substrate hydrolysis. Additional struc-
firm all protein and peptide products. 1 H-15N HSQC spectra of the
tural characterization of NS3/NS4A complexes in solu- NS3 2a (1–192) and NS3 2a (1–181)Lys6 were identical (except for
tion is needed to understand its role in more detail. the C-terminal residues), indicating that both protein constructs
adopted the same structure in solution.
The boronic-acid peptidic inhibitor, Ac-Asp-Glu-Val-Val-Pro-bor-Experimental Procedures
oAlg-OH, corresponds to the P6-P1 cleavage product of the NS5A-
NS5B site. The inhibitor was synthesized according to publishedProtein and Peptide Production
procedures (C.A.K., S.J., and T.P. Forsyth, peptide boronic acidRNAzol B (TelTest) was used to extract viral RNA from a sample of
inhibitors of hepatitis C virus protease, patent WO2001002424,HCV 2a-infected human serum. The viral RNA was used as a tem-
2001).plate for RT/PCR to amplify the NS3 region (amino acids 1027–1218)
with the following gene specific primers: CAGCTGCAGCCATGGCC
CCCATCACTGCTTAT and CCGAAGCTTTCAAGCAGGTGGTGTGCT NMR Spectroscopy
All NMR experiments were carried out at 25C on protein [60 M–1GTT. The ends of the amplified fragment were engineered to contain
PstI (5) and HindIII (3) restriction enzyme sites and a stop codon. mM] in sample buffer of 25 mM MES (2-[N-morpholinio]ethanesul-
fonic acid) buffer (pH 6.5), 100 mM NaCl, 5 mM DTT, and 2% glycerolAfter digestion with PstI and HindIII, the DNA fragment was ligated
to the PstI and HindIII sites in the vector pTrcHisB (Invitrogen), which in 94% H2O/6% D2O, unless noted otherwise. Samples were placed
in either a 5 mm Shigemi microtube or a 5 mm Wilmad tube. Whenprovided an amino-terminal histidine tag. Subsequently, the 5 end
was reengineered to contain an NdeI site and amino terminal methio- stored with sodium azide and NS3 inhibitor, samples were stable
for months at 4C.nine and subcloned into the NdeI and HindIII sites of the vector
pET3AM for expression of the protein without an amino-terminal NMR data were acquired on a four-channel Bruker 600 MHz
Avance spectrometer equipped with a Bruker triple resonance, triplehistidine tag.
An alternative NS3 2a construct [NS3 2a (1–181)Lys6] was derived axis gradient probe. Chemical shifts were referenced to 10 mM DSS/
D2O at 25C as described in Wishart et al. [51]. The NMR experimen-by cloning this DNA fragment into the pET24b vector (Novagen) at
the NdeI/Hind III site. The NS3 gene was amplified with two PCR tal parameters are listed in Table 2. In all experiments, water magne-
tization was maintained along the z axis to avoid saturation of pro-primers: a 5 PCR primer (GGATTCCATATGGCTCCGATCGCTTAC)
encoding an NdeI site and amino acids MAPITAY and a 3 PCR tons undergoing exchange [52], and gradients were used to dephase
unwanted magnetization [53].primer (CCCAAGCTTTCACTTTTTCTTTTTCTTTTTCGACCGTGTAG
CGATGTCGAGAGA) complementary to amino acid residues 1201– NS3/NS4A/InhI in 94% H2O/6% D2O was exchanged into D2O by
diluting the sample 25-fold with D2O sample buffer, concentrating1207. This 3 primer was followed by a KKKKKK tag, and the stop
codon was flanked by a HindIII site. Codons optimized for E. coli in a 5K MWCO Biomax (Millipore), then diluting and concentrating
again. After the sample was brought to 25C, a series of 1 H-15Nwere used for the first seven N-terminal residues to improve expres-
sion levels. Taq DNA polymerase (Life Technology) was used for HSQC spectra were acquired to identify protons in slow exchange
with water. The D2O sample was then used for a 2D 1 H-15N long-DNA amplification, and DNA was purified and digested with NdeI
and HindIII. The DNA was ligated into the expression vector pET24b range HSQC centered at 180 ppm. A 22 ms delay was employed to
allow evolution of long-range 1 HC-15N couplings. A titration of thewith a ligation kit (Pharmacia’s Ready-To-Go T4 DNA Ligase) and
was sequenced to confirm the construct. side chain histidines was obtained by incremental pH adjustments
(pH 6.5, 7.0, 7.5, 8.1, 9.1, and 10.4) and 2D 1 H-15N long-range HSQCThe recombinant vectors were transformed into E. coli BL21 (DE3)
cells. Cells were grown at 20C in MOPS minimal media containing experiments.
NMR data were processed with nmrPipe [54] processing software(15NH4)2SO4, [13C6]glucose or unlabeled glucose, 3.0 g/l labeled Isogro
(Isotec), and micronutrients [46]. The protein was purified according and analyzed with nmrWish, PIPP [55] and ANSIG [56, 57] software
packages. Peak picking and sorting routines in the PIPP programto published procedures with minor modifications [46, 49]. In brief,
the cells were harvested and resuspended in 1 PBS (pH 7.4), 10% were used to identify the {HNi, Ni, Ci, Ci} and {HNi, Ni, Ci-1, Ci-1}
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spin systems and to determine the initial sequential backbone as- Smith, E.B., Hart, A.M., Ingram, R., Durkin, J., Mui, P.W., et al.
(1996). Enhancement of hepatitis C virus NS3 proteinase activitysignments. Completion of the backbone assignments and all subse-
quent data analysis were done with ANSIG and nmrWish. by association with NS4A-specific synthetic peptides: identifi-
cation of sequence and critical residues of NS4A for the cofactor
activity. Virology 225, 328–338.Enzymology
6. Kim, J.L., Morgenstern, K.A., Lin, C., Fox, T., Dwyer, M.D., Lan-The peptide substrate, Ac-Asp-Glu-Asp(Edans)-Glu-Glu-Abu
dro, J.A., Chambers, S.P., Markland, W., Lepre, C.A., et al.[COO]Ala-Ser-Lys(Dabcy)-NH2, has been described previously for
(1996). Crystal structure of the hepatitis C virus NS3 proteaseHCV protease [33]. It was prepared by the published procedure.
domain complexed with a synthetic NS4A cofactor peptide. CellPeptide hydrolysis was measured either by monitoring the appear-
87, 343–355.ance of cleavage products by HPLC or by measuring the fluores-
7. Yan, Y., Li, Y., Munshi, S., Sardana, V., Cole, J.L., Sardana, M.,cence increase that is concurrent with peptide hydrolysis.
Steinkuehler, C., Tomei, L., De Francesco, R., Kuo, L.C., et al.For the HPLC assay, NS3 (0.38 nM) was incubated with NS4A (10
(1998). Complex of NS3 protease and NS4A peptide of BK strainM) for 5 min at 25C in 50 mM HEPES buffer (pH 7.0) containing
hepatitis C virus: a 2.2 A˚ resolution structure in a hexagonal150 mM NaCl, 5 mM DTT, 0.1% maltopyranoside, and 15% glycerol.
crystal form. Protein Sci. 7, 837–847.Substrate was added, and after 10 min, hydrolysis reactions were
8. Love, R.A., Parge, H.E., Wickersham, J.A., Hostomsky, Z., Ha-quenched by the addition of 3.0 l of 10% TFA to 150 l reaction
buka, N., Moomaw, E.W., Adachi, T., Margosiak, S., Dagostino,solutions. Levels of hydrolysis were determined by HPLC. Aliquots
E., and Hostomska, Z. (1998). The conformation of hepatitis C(50 l) were injected on HPLC, and linear gradients from 90% water,
virus NS3 proteinase with and without NS4A: a structural basis10% acetonitrile, and 0.1% TFA to 90% acetonitrile were run at a
for the activation of the enzyme by its cofactor. Clin. Diagn.flow rate of 1.0 ml/min over a period of 30 min. HPLCs were run on
Virol. 10, 151–156.a HP1090 with a 4.6  250 mm C18 column (Rainin, #83-201-C)
9. Yao, N., Reichert, P., Taremi, S.S., Prosise, W.W., and Weber,equipped with a fluorescent detector with excitation and emission
P.C. (1999). Molecular views of viral polyprotein processing re-wavelengths set to 350 and 500 nm, respectively. Levels of hydroly-
vealed by the crystal structure of the hepatitis C virus bifunc-sis were determined by measuring the area of the fluorescent peak
tional protease-helicase. Struct. Fold. Des. 7, 1353–1363.at 5.3 min. Complete hydrolysis of a 5.0 M sample gave an area
10. Love, R.A., Parge, H.E., Wickersham, J.A., Hostomsky, Z., Ha-of 3.4 fluorescent units.
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